سعر اندوسيبتيف 30/75مكجم 21 قرص 2024

Combined oral contraceptive coated tablets containing ethinylestradiol 30 micrograms and gestodene 75 micrograms (Al Andalous Pharmaceutical Industries); 21 tablets per pack.

• Oral contraceptionPopulation: Women of reproductive ageelectronic medicines compendium (emc), UK
• Oral contraceptionPopulation: Women of reproductive ageAl Andalous Pharmaceutical Industries (manufacturer website)

• Common: nausea, abdominal pain, weight increase, headache, depressed or altered mood, breast pain/tenderness. Serious: venous and arterial thromboembolism.International label, same formulation · electronic medicines compendium (emc), UK

• Presence or risk of venous thromboembolism (current or past VTE, known hereditary predisposition, major surgery with prolonged immobilisation, multiple risk factors).International label, same formulation · electronic medicines compendium (emc), UK
• Presence or risk of arterial thromboembolism: myocardial infarction, stroke, angina, TIA; migraine with focal neurological symptoms; diabetes with vascular symptoms, severe hypertension or severe dyslipoproteinaemia.International label, same formulation · electronic medicines compendium (emc), UK
• Severe hepatic disease with abnormal liver function, liver tumours, known or suspected sex-steroid-dependent malignancy (e.g., breast cancer), hypersensitivity.International label, same formulation · electronic medicines compendium (emc), UK

• Combined hormonal contraceptives increase VTE risk; gestodene-containing products may carry up to twice the risk of levonorgestrel-containing ones (about 9-12 per 10,000 women per year vs about 2 in non-users).International label, same formulation · electronic medicines compendium (emc), UK
• Seek urgent medical attention for symptoms of thrombosis (unilateral leg swelling/pain, sudden breathlessness, chest pain, sudden neurological symptoms).International label, same formulation · electronic medicines compendium (emc), UK

• Hepatic enzyme (CYP3A4) inducers, e.g., phenytoin, barbiturates, carbamazepine, rifampicin, St John's wortMay cause contraceptive failure and breakthrough bleeding; use a barrier method during treatment and for 28 days after stopping the inducer.electronic medicines compendium (emc), UK
• Ombitasvir/paritaprevir/ritonavir ± dasabuvir; glecaprevir/pibrentasvir; sofosbuvir/velpatasvir/voxilaprevirContraindicated (risk of ALT elevations).electronic medicines compendium (emc), UK

• Not indicated during pregnancy; stop if pregnancy occurs. Epidemiological studies show no increased risk of birth defects or teratogenicity from inadvertent use.International label, same formulation · electronic medicines compendium (emc), UK
• May reduce the quantity and alter the composition of breast milk; generally not recommended until weaning - use another contraceptive method.International label, same formulation · electronic medicines compendium (emc), UK

• Ethinylestradiol: As part of an estrogen-progestogen combination: inhibits ovulation by suppressing the mid-cycle LH surge, thickens cervical mucus and makes the endometrium unreceptive to implantation.
• Gestodene: As part of an estrogen-progestogen combination: inhibits ovulation by suppressing the mid-cycle LH surge, thickens cervical mucus and makes the endometrium unreceptive to implantation.